We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tarsus Pharmaceuticals Inc | NASDAQ:TARS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.31 | 0.96% | 32.60 | 32.60 | 32.66 | 32.8479 | 31.45 | 31.705 | 92,475 | 16:07:15 |
All dates and times listed above are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.tarsusrx.com for the latest information.
A live webcast of the presentation will also be available on the events section of the Tarsus website. The replay will be available within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying three investigational medicines in clinical trials, including TP-03 for the treatment of Meibomian Gland Disease, which is currently being studied in a Phase 2a clinical trial, TP-04 for the potential treatment of Rosacea and TP-05, an oral tablet for the prevention of Lyme disease. TP-04 and TP-05 are both currently being studied in Phase 2a clinical trials to evaluate safety, tolerability, and proof-of activity.
Media Contact: |
Adrienne Kemp |
Sr. Director, Corporate Communications |
(949) 922-0801 |
AKemp@tarsusrx.com |
Investor Contact: |
David Nakasone |
Head of Investor Relations |
(949) 620-3223 |
DNakasone@tarsusrx.com |
1 Year Tarsus Pharmaceuticals Chart |
1 Month Tarsus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions